Protagonist Q3 net loss $31.2M, cash $267.4M; rusfertide Phase 3 enrollment delayed to H2 2023

Protagonist Therapeutics, Inc

2022-Q3 EPS reported -$1.90 revenue$26,581,000

Net loss $31.2M ($0.64 per share) vs $33.8M ($0.70) in Q3 2021; no license revenue vs $10.3M.
Cash and securities $267.4M as of Sep 30; expected to fund operations through end of 2024.
Phase 3 VERIFY enrollment completion expected H2 2023 due to site staff shortages.
Appointed Arturo Molina, M.D., M.S. as CMO, prioritizing rusfertide program.
De-prioritized PN-943; no further internal resources; seeking out-licensing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Protagonist Therapeutics, Inc reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported financial results for the third quarter ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-22-115933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.